# Thermo Fisher

Streamlining workflow from characterization to monitoring of therapeutic oligonucleotides impurities using Orbitrap based LC-HRAM-MS platforms

Hao Yang, PhD April 11, 2023

The world leader in serving science



## Agenda

- Oligonucleotides applications and analytical challenges
- Application benefits of using
  - Vanquish UHPLC system and consumables
  - Orbitrap Exploris 240 and Orbitrap Exploris MX
  - Biopharma Finder (BPF) 5.0 and Chromeleon (CM) 7.3.1
- Oligonucleotide workflow solution
  - Oligonucleotide characterization using BPF 5.0
  - Impurities monitoring using CM 7.3.1
  - Oligo system performance evaluation test (SET)



## **Oligonucleotide Applications**



- Synthetic DNA primers
- Unmodified, PCR analysis
- Typically, around18 30 bases
- High demand



- Therapeutic oligos (e.g., <u>siRNA</u> and ASO)
- Around 20mer in length, heavily modified
- 15 FDA approved drugs\*
- miRNAs/sgRNA (up to 120mer)
   \* https://doi.org/10.2217/frd-202-0008



- mRNA vaccines
- Up to 5,000 nucleotides
- Sequencing requires digestion
- Associated with <u>LNP</u> and viral vectors for delivery
- <u>mRNA direct sequence</u>
   <u>mapping</u> application



## **Therapeutic Oligonucleotides**

T	he	m	10	F	ist	ner
S	CΙ	Е	Ν	Т	I F	I C

Target	<ul> <li>Single stranded antisense oligos, miRNA/sgRNAs, double stranded siRNAs</li> <li>Variable length 20 – 120 nucleotides</li> <li>Heavily modified (e.g., PS, 2'O-Met/F/MOE, LNA, etc.)</li> <li>Product related impurities (e.g., n-x, n+x, base modifications, etc)</li> </ul>
Requirement	<ul> <li>Mass confirmation via intact mass deconvolution</li> <li>Sequence confirmation base-by-base with localization of modification</li> <li>Relative quantitation of product and its impurities</li> </ul>
Challenges	<ul> <li>Lack of robust analytical methods to characterize oligonucleotides with increased complexity</li> <li>Salt adducts can impede accurate mass determination</li> <li>Lack of software tool for sequence identification, and automated peak annotation with confidence</li> </ul>

## **State-of-the-art Technologies for Oligonucleotide Analysis**

#### Application benefit highlights



**Thermo Fisher** 

## **ChromeCare™ LC-MS Solvents**

Importance of clean solvents





Low metal adduct formation improves quantitation and intact mass deconvolution

## **Robust and Reproducible IPRP-LC Separation**

Vanquish Horizon UHPLC equipped with DNAPac RP column 2.1 x 250 mm, 4 µm



## **Power of High-Resolution Accurate Mass (HRAM)**



Thermo Físher

## **BioPharma Finder Software Offers a Complete Oligonucleotide Analysis**

Thermo Fisher



- Support DNA or RNA
- Enter sequence in a plain or triplet format
- Edit sequence to set constant modification
- Assign variable modifications
- Custom building blocks and variable modifications

# Automatic MS<sup>2</sup> Annotation



- Fast and confident oligo
   identification and mapping
   using ddMS<sup>2</sup> data
- Predicted vs annotated experimental MS<sup>2</sup> spectra
- Fragment and sequence coverage maps
- Average structural resolutions (ASR) score

## Relative Quantitation of Impurities



- Identification, mapping, and relative quantitation of oligo impurities in one experiment
- Custom list of components for % abundance calculation
- Modification summary table and plot

## Comparative Data Analysis



- Comparative analysis of multiple ddMS<sup>2</sup> raw files facilitates method optimization
- An array of features, such as chromatograms, fragment coverage map, MS<sup>2</sup> spectra, MS area, ASR score, can be compared

## **Chromeleon eCDS**



**Thermo Fisher** 

SCIEN

## Agenda

- Oligonucleotides applications and analytical challenges
- Application benefits of using
  - Vanquish UHPLC system and consumables
  - Orbitrap Exploris 240 and MX
  - Biopharma Finder (BPF) 5.0 and Chromeleon (CM) 7.3.1
- Oligonucleotide workflow solution
  - Oligonucleotide characterization using BPF 5.0
  - Impurities monitoring using CM 7.3.1
  - Oligo system performance evaluation test (SET)



## **Oligonucleotide Workflow Solution**

From characterization to monitoring of oligonucleotide impurities using Orbitrap based LC-HRAM-MS platforms

**Thermo Fisher** 



#### Confident identification based on Mass Accuracy and MS/MS spectra matching to predicted





#### Fragment Coverage Map

Ur-pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pUr-pGr (-5)

Average Structural Resolution = 1.0 residues

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Ur	-pUf-	-pGr-	-pAr-	-pCr-	-pAr-	-pCr-	-pCr-	-pAr-	-pGr-	-pAr-	-pCr-	-pCr-	-pAr-	-pAf-	-pCr-	-pUr-	-pGr-	-pGr-	-pUr-	-pAr-	-pAr-	-pUr-	-pG
24	23	22	21	20	19	18	17	16	15	14	13	12	11	10	9	8	7	6	5	4	3	2	1

Average structural resolution (ASR) value of 1.0 means every single nucleotide residue bond has been broken and resulting fragment ions matched the predicted MS/MS spectra

Color Co	ode for Io	on Intensi	ity	
>6.0e+04	>3.5e+04	>2.1e+04	>1.2e+04	>7.2e+

	Ur-pUf-pGr-pAr-pCr-	pAr-pCr-pCr-pAr-pC	л рАг-рСг-	-pCr-pAr-	pAf-pCr-pUr	-pGr-pGr-pUr-p	Ar-pAr-pUr	-pGı
			c21[4-](1685.2)				y3	
		c20	[4-](1602.7)				y4(1246.2)	
		c19[4-	](1526.7)				w5[2-](815.6)	
		c18[3-](19	920.2)			yé	5[2-](948.1)	
		c17[3-](1805	.2)			y7[2-]	(1121.2)	
		c16[3-](1703.2)				y8[2-](12	.74.2)	
		c14[3-](1491.2)				w10[2-](1632.2)		
		c13[3-](1381.2)				w11[3-](1198.1)		
r	(	c12[3-](1279.5)			1	w12[3-](1299.2)		
	c11	[2-](1767.2)			y13	8[3-](1374.2)		
	a10-B[2	-](1487.2)			y14[3-]	](1484.2)		
	c9[2-](14	30.2)			y15[3-](15	599.2)		
	c8[2-](1265.2	2)			y16[3-](1709	.2)		
	c7[2-](1112.6)				y17[3-](1810.9)			
	c6[2-](960.1)			yl	18[3-](1912.3)			
	c5[2-](795.6)			y19[4	4-](1516.2)			
	c4(1287.1)			y20[4-](	1592.2)			
	d3					z9[2-](1417.)	2)	
	c2		у	22[4-](1761.2	)			
1			y23[	[4-](1838.2)				
							3	72

Results																	
₽		Leve	No.	Identification	Oligo Sequence	Mod	Site	Δ ppm	Conf. Score	Best ASR	ID Type	RT	M/Z	Charge St.	Mono Mass Exp.	Avg Mass Exp.	Theor. Mass
V <sub>x</sub>		V <sub>×</sub> <u>A</u> a ∖	¢ = 1	Aa 👻 🗸	<u>A</u> a <b>▼</b> 1 <sub>2</sub>	= (No •	V <sub>×</sub> <u>A</u> a ◄	$v_{x} = -v_{x}$	. = • v.	≤ <b>▼</b> 7 <sub>×</sub>	= • T <sub>x</sub>	$\tau_{\rm s} = \tau_{\rm s}$	= • T <sub>x</sub>	$= \cdot v_{\!\scriptscriptstyle \rm x}$	= • V <sub>x</sub>	= • T <sub>x</sub>	= • T <sub>x</sub>
0 🕨 13		C	14	1:U2-G24 = 7354.042m[nonspecific]	pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	nonspecific		-1.97	100.0	1.0	MS2	14.00	918.622	-8	7354.0273	7357.46	7354.0418
0 14		C	15	1:U2-G24 = 7354.042m[nonspecific]	pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	nonspecific		-2.37	100.0	1.1	MS2	14.01	1049.996	-7	7354.0244	7357.45	7354.0418
9 15		C	16	1:U2-G24 = 7354.042m[nonspecific]	pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	nonspecific		-2.03	100.0	1.1	MS2	14.01	816.440	-9	7354.0269	7357.72	7354.0418
16		C	26	1:U1-G24 = 7676.0619m(~C13+Oxidation)	Ur-pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pUr-pAr-pAr-pAr-pUr-pGr	Oxidation	~C13	-0.70	53.4	1.1	MS2	14.28	852.109	-9	7676.0566	7679.20	7676.0620
17		C	55	1:U1-G24 = 7660.067m	Ur-pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pUr-pAr-pAr-pAr-pUr-pGr	None		-3.79	100.0	1.0	MS2	14.36	637.496	-12	7660.0381	7663.72	7660.0671
) 18		C	58	1:U1-G24 = 7660.067m	Ur-pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pUr-pAr-pAr-pAr-pUr-pGr	None		-3.22	100.0	1.0	MS2	14.36	695.633	-11	7660.0425	7663.39	7660.0671
9 19		C	60	1:U1-G24 = 7660.067m	Ur-pUf-pGr-pAr-pCr-pAr-pCr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	None		-2.77	100.0	1.0	MS2	14.36	765.298	-10	7660.0459	7663.40	7660.0671
0 🕨 20		C	68	1:U1-G24 = 7660.067m	Ur-pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pUr-pGr-pUr-pAr-pAr-pUr-pGr	None		-2.96	i 100.0	1.0	MS2	14.37	1531.603	-5	7660.0444	7663.41	7660.0671
9 21		C	69	1:U1-G24 = 7660.067m	Ur-pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pUr-pAr-pAr-pUr-pGr	None		-2.96	100.0	1.0	MS2	14.37	1276.167	-6	7660.0444	7663.39	7660.0671
9 22		C	74	1:U1-G24 = 7660.067m	Ur-pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	None		-2.26	100.0	1.0	MS2	14.38	850.443	-9	7660.0498	7663.38	7660.0671
	_																

High confidence score with low ∆ppm and low ASR value provides accurate and confident sequence identification and confirmation



Results															
Ē	ŧ.		Identification	Mod	Site	M/Z	Charge St.	Mono Mass Exp.	Avg Mass Exp.	Theor. Mass	Δppm	Conf. Score	Best ASR	RT	MS Area
V <sub>x</sub>			Aa 🗸 🗸	<u>A</u> a 👻 🖡	<u>A</u> a T <sub>x</sub>	= • X <sub>2</sub>	= • V <sub>x</sub>	= • V_x	= • V <sub>x</sub>	= • X,	≤ <b>▼</b> V <sub>×</sub>	≥ ▼ V <sub>x</sub>	$= . \ \textbf{v}_{x}$	$= \cdot \tau_{\rm s}$	= • V.
€ ► 5	51		1:U1-G24 = 7351.0347m(~C13+RNA_Cytosine triple loss)	RNA_Cytosine triple loss	~C13	1469.797	-5	7351.0225	7354.13	7351.0345	-1.64	99.9	1.0	11.27	414,045.41
• 5	52		1:U1-G24 = 7351.0347m(~C13+RNA_Cytosine triple loss)	RNA_Cytosine triple loss	~C13	1049.424	-7	0.0000	7354.12	7351.0347	0.00	99.9	1.0	11.27	753,516.56
÷ 5	53		1:U1-G24 = 7351.0347m(~C13+RNA_Cytosine triple loss)	RNA_Cytosine triple loss	~C13	1224.663	-6	7351.0215	7354.13	7351.0345	-1.77	99.9	1.0	11.27	553,913.81
Ð 5	54		1:U1-G24 = 7351.0347m(~C13+RNA_Cytosine triple loss)	RNA_Cytosine triple loss	~C13	918.121	-8	7351.0283	7354.17	7351.0345	-0.84	99.9	1.0	11.27	815,708.62
• 5	55		1:U1-G24 = 7351.0347m(~C13+RNA_Cytosine triple loss)	RNA_Cytosine triple loss	~C13	734.395	-10	7351.0225	7354.17	7351.0345	-1.64	99.9	1.0	11.27	457,254.94
⊕ 5	56		1:U1-G24 = 7351.0347m(~C13+RNA_Cytosine triple loss)	RNA_Cytosine triple loss	~C13	816.107	-9	7351.0273	7354.12	7351.0345	-0.97	<mark>99.9</mark>	1.0	11.27	868,029.06
		10000													

#### Provide base-by-base sequence information and localization of modifications



**Thermo Fisher** 

Provide base-by-base sequence information and localization of modifications

# **NCE Energy Optimization**

## Higher the NCE energy, more internal fragmentation, not ideal for long oligos



# **NCE Energy Optimization**

## Higher the NCE energy, more internal fragmentation, not ideal for long oligos



# **NCE Energy Optimization**

Higher the NCE energy, more internal fragmentation, not ideal for long oligos



#### Thermo Fisher SCIENTIFIC

#### Fragment Coverage Map



### **NCE 13**

## **Create Oligonucleotide Component List for Monitoring**

Result	ts														
	₽	✓	Level	No.	Identification	Oligo Sequence +	Mod	Site	Δ ppm	Conf. Score	Best ASR	RT	M/Z	Charge St.	Mono Mass Exp.
V <sub>x</sub>	ĸ	$\blacksquare = \mathbb{T}_{\mathbf{x}}$	<u>A</u> a T <sub>×</sub>	$= T_{x}$	, <u>A</u> a → T <sub>s</sub>	= (NonBlanks) • V <sub>x</sub>	<u>A</u> a (C ▼ ¥,	<u>A</u> a 🔻 🔨	$=$ $\forall_{s}$	$\geq \ \dots \ \forall_x$	$=$ $\cdot$ $T_{x}$	$= \ \cdot \ v_{\star}$	= • V <sub>x</sub>	= • V <sub>*</sub>	= • T <sub>x</sub>
•	1		Comp	2	1:A15-G24 = 3185.4570m[nonspecific]	pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	nonspecific		-1.89	100.0	1.1	4.12	795.606	-4	3185.4509
•	2	$\checkmark$	Comp	3	1:A15-G24 = 3185.4570m[nonspecific]	pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	nonspecific		-2.43	100.0	1.0	4.12	636.283	-5	3185.4492
•	3	$\checkmark$	Comp	4	1:A15-G24 = 3185.4570m[nonspecific]	pAf-pCr-pUr-pGr-pUr-pAr-pAr-pUr-pGr 🏲 N = 14	nonspecific		-1.81	100.0	1.1	4.12	1061.143	-3	3185.4512
•	4	$\checkmark$	Comp	5	1:A15-G24 = 3185.4570m[nonspecific]	pAf-pCr-pUr-pGr-pGr-pUr-pAr-pUr-pGr	nonspecific		-2.04	100.0	1.1	4.12	1592.219	-2	3185.4504
•	5	$\checkmark$	Comp	6	1:A14-G24 = 3514.5095m[nonspecific]	pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pUr-pGr	nonspecific		-1.93	100.0	1.0	5.16	877.869	-4	3514.5027
•	6	$\checkmark$	Comp	7	1:A14-G24 = 3514.5095m[nonspecific]	pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pUr-pGr	nonspecific		-2.83	100.0	1.0	5.16	1170.827	-3	3514.4995
•	7	1	Comp	8	1:A14-G24 = 3514.5095m[nonspecific]	pAr-pAf-pCr-pUr-pGr-pUr-pAr-pAr-pUr-pGr	nonspecific		-2.69	100.0	1.0	5.16	584.910	-6	3514.5000
•	8	1	Comp	10	1:A14-G24 = 3514.5095m[nonspecific]	pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pUr-pGr	nonspecific		-2.28	100.0	1.0	5.16	702.094	-5	3514.5015
•	9	1	Comp	12	1:U2-G24 = 7354.042m[nonspecific]	pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	nonspecific		-2.50	100.0	1.1	13.99	1225.164	-6	7354.0234
•	10	4	Comp	13	1:U2-G24 = 7354.042m[nonspecific]	pUf-pGr-pAr-pCr-pAr-pCr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	nonspecific		-1.97	100.0	1.3	13.99	1470.398	-5	7354.0273
•	11	1	Comp	14	1:U2-G24 = 7354.042m[nonspecific]	pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	nonspecific	1 - 1	-1.97	100.0	1.0	14.00	918.622	-8	7354.0273
•	12	1	Comp	15	1:U2-G24 = 7354.042m[nonspecific]	pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	nonspecific		-2.37	100.0	1.1	14.01	1049.996	-7	7354.0244
•	13	4	Comp	16	1:U2-G24 = 7354.042m[nonspecific]	pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	nonspecific		-2.03	100.0	1.1	14.01	816.440	-9	7354.0269
•	14	$\checkmark$	Comp	11	1:U1-G24 = 7660.067m	Ur-pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	None		-2.01	88.4	1.4	13.98	956.875	-8	7660.0518
•	15	$\checkmark$	Comp	55	1:U1-G24 = 7660.067m	Ur-pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	None		-3.79	100.0	1.0	14.36	637.496	-12	7660.0381
•	16	$\checkmark$	Comp	58	1:U1-G24 = 7660.067m	Ur-pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	None		-3.22	100.0	1.0	14.36	695.633	-11	7660.0425
•	17	$\checkmark$	Comp	60	1:U1-G24 = 7660.067m	Ur-pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	None		-2.77	100.0	1.0	14.36	765.298	-10	7660.0459
•	18	$\checkmark$	Comp	68	3 1:U1-G24 = 7660.067m	Ur-pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	None		-2.96	100.0	1.0	14.37	1531.603	-5	7660.0444
•	19	$\checkmark$	Comp	69	1:U1-G24 = 7660.067m	Ur-pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	None		-2.96	100.0	1.0	14.37	1276.167	-6	7660.0444
•	20	$\checkmark$	Comp	74	1:U1-G24 = 7660.067m	Ur-pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	None		-2.26	100.0	1.0	14.38	850.443	-9	7660.0498
•	21	<b>√</b>	Comp	75	1:U1-G24 = 7660.067m	Ur-pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	None		-2.39	100.0	1.0	14.38	1093.714	-7	7660.0488
÷ 🕨	22	-	Comp	77	1:U1-G24 = 7660.067m	Ur-pUf-pGr-pAr-pCr-pAr-pCr-pAr-pGr-pAr-pCr-pCr-pAr-pAf-pCr-pUr-pGr-pGr-pUr-pAr-pAr-pUr-pGr	None		-2.39	100.0	1.0	14.38	956.874	-8	7660.0488

Conf. Score ≥ 80

**ASR** ≤ 1.5

**∆ppm ≤ 10** 

**Thermo Fisher** 

#### **Thermo Fisher** SCIENTIFIC

## **Chromeleon CDS for Oligonucleotide Monitoring**

#### Relative quantitation of oligonucleotide impurities using Chromeleon 7.3.1



oPharma Data F	ath: D:	\Hao Yang\Oligo Analysis\Demo OE240\24mer RNA 2F	longcolumn ne	w MP new sa	mple_2.bpf							m
PrecursorMas	s	Name	RT 🔺	Charge	Peptide Group	Isotope 1	Isotope 2	Isotope 3	Isotope 4	Isotope 5	Isot 🗾	
653.08	20 💌	ACUGGUAAUG	4.260	5	1	653.08520	653.28571	653.48621	653.68669	653.88718	654.08766	654.28
816.35	37 🔽	ACUGGUAAUG - Isomer 2	4.266	4	1	816.35637	816.60701	816.85763	817.10824	817.35885	817.60944	817.86
1632.71	19 💌	ACUGGUAAUG - Isomer 3	4.297	2	1	1632.71219	1633.21350	1633.71475	1634.21597	1634.71715	1635.21834	1635.719
1088.47	97 🔽	ACUGGUAAUG - Isomer 4	4.389	3	1	1088.47497	1088.80917	1089.14333	1089.47749	1089.81162	1090.14573	1090.479
599.07	85 🔽	AACUGGUAAUG	5.216	6	1	599.07985	599.24693	599.41401	599.58108	599.74815	599.91522	600.08
718.89	71 🔽	AACUGGUAAUG - Isomer 2	5.234	5	1	718.89571	719.09621	719.29671	719.49720	719.69768	719.89816	720.09
898.61	50 💌	AACUGGUAAUG - Isomer 3	5.244	4	1	898.61950	898.87014	899.12076	899.37137	899.62198	899.87257	900.12:
1198.15	15 🔽	AACUGGUAAUG - Isomer 4	5.255	3	1	1198.15915	1198.49334	1198.82750	1199.16166	1199.49580	1199.82991	1200.164
957.50	94 🔽	UUGACACCAGACCAACUGGUAAUG	13.853	8	1	957.50894	957.63425	957.75957	957.88488	958.01019	958.13550	958.26
1486.80	18 🔽	UGACACCAGACCAACUGGUAAUG	13.906	5	1	1486.80218	1487.00268	1487.20319	1487.40370	1487.60420	1487.80470	1488.005
1239.00	91 🔽	UGACACCAGACCAACUGGUAAUG - Isomer 2	13.917	6	1	1239.00191	1239.16899	1239.33608	1239.50317	1239.67025	1239.83733	1240.004
929.25	57 🔽	UGACACCAGACCAACUGGUAAUG - Isomer 3	13.919	8	1	929.25157	929.37688	929.50219	929.62751	929.75282	929.87812	930.00



21 Proprietary & Confidential | hao.yang@thermofisher.com | 7/17/2022

## **Chromeleon eWorkflow Procedure**

Harmonized instrument HW and SW enable seamless method transfer between Orbitrap Exploris platforms

## Direct method transfer without physically moving any method files





#### **Characterization setup:**

- Vanquish Horizon UHPLC
- Orbitrap Exploris 240 Mass Spectrometer

22



#### eWorkflow procedure

- LC & MS acquisition methods
- Injection sequence
- Result view template
- Processing method
- Report template



#### Monitoring setup #1:

Thermo Fishei

- Vanquish Flex UHPLC
- **Orbitrap Exploris MX** mass detector



#### Monitoring setup #2:

- Vanquish Flex UHPLC
- **Orbitrap Exploris MX** mass detector

Proprietary & Confidential | hao.yang@thermofisher.com | 7/17/2022

## **Oligonucleotide Impurities Profiling**



## LC-HRAM-MS



\* % relative abundances and %RSDs are calculated based on triplicate injections of 24mer RNA with 2'F modifications

## **Oligonucleotide SET**

## System performance tested against pre-defined acceptance criteria

Performance check	Oligonucleotides Sequence	System performance metrics	Acceptance criteria
LC-MS test	<ol> <li>GAG CGG CTG T (10mer)</li> <li>GAG CGG CTG TGA GCG GCT GT (20mer)</li> <li>GAG CGG CTG TGA GCG GCT GTG AGC GGC TGT (30mer)</li> <li>GAG CGG CTG TGA GCG GCT GTG AGC GGC TGT GAG CGG CTG T (40mer)</li> <li>GAG CGG CTG TGA GCG GCT GTG AGC GGC TGT GAG CGG CTG TGA GCG GCT GT</li> </ol>	<ul> <li>Retention time reproducibility</li> <li>Peak area reproducibility</li> <li>Peak height reproducibility</li> <li>Peak height range</li> <li>Peak width at 10% height reproducibility</li> <li>Peak width at 10% height</li> <li>Peak width at 10% height</li> </ul>	<ul> <li>RT %RSD ≤ 2%</li> <li>Peak area %RSD ≤ 10%</li> <li>Peak height %RSD ≤ 10%</li> <li>Peak height range between 2E7 to 2E8 counts</li> <li>Peak width at 10% height %RSD ≤ 10%</li> <li>Peak width at 10% height % 0.5 min</li> </ul>
Intact mass deconvolution	(50mer) 6. GAG CGG CTG TGA GCG GCT GTG AGC GGC TGT GAG CGG CTG TGA GCG GCT GTG AGC G (55mer)	<ul> <li>Mass accuracy of deconvoluted FLP mass</li> <li>% Fractional abundance of Na and K adducts</li> </ul>	<ul> <li>Mass accuracy of deconvoluted FLP mass ≤ 5 ppm</li> <li>% Fractional abundance of Na, and K adducts ≤ 10%</li> </ul>

#### **Oligonucleotide SET**

- Oligonucleotide standards (6 unmodified, ssDNA sequences)
- A sequence containing 10 injections using full MS method only, can be seamlessly deployed using Chromeleon eWorkflow procedure
- Evaluates LC and MS instrument performance related metrics that are important for oligonucleotide applications based on pre-defined acceptance criteria with pass or fail status



# **Oligonucleotide SET**

#### System performance tested against pre-defined acceptance criteria

Performance check	Oligonucleotides Sequence	System performance metrics	Acceptance criteria
LC-MS test	<ol> <li>GAG CGG CTG T (10mer)</li> <li>GAG CGG CTG TGA GCG GCT GT (20mer)</li> <li>GAG CGG CTG TGA GCG GCT GTG AGC GGC TGT (30mer)</li> <li>GAG CGG CTG TGA GCG GCT GTG AGC GGC TGT GAG CGG CTG T (40mer)</li> <li>GAG CGG CTG TGA GCG GCT GTG AGC GGC TGT GAG CGG CTG TGA GCG GCT GT</li> </ol>	<ul> <li>Retention time reproducibility</li> <li>Peak area reproducibility</li> <li>Peak height reproducibility</li> <li>Peak height range</li> <li>Peak width at 10% height reproducibility</li> <li>Peak width at 10% height</li> </ul>	<ul> <li>RT %RSD ≤ 2%</li> <li>Peak area %RSD ≤ 10%</li> <li>Peak height %RSD ≤ 10%</li> <li>Peak height range between 2E7 to 2E8 counts</li> <li>Peak width at 10% height %RSD ≤ 10%</li> <li>Peak width at 10% height ≤ 0.5 min</li> </ul>
Intact mass deconvolution	(50mer) 6. GAG CGG CTG TGA GCG GCT GTG AGC GGC TGT GAG CGG CTG TGA GCG GCT GTG AGC G (55mer)	<ul> <li>Mass accuracy of deconvoluted FLP mass</li> <li>% Fractional abundance of Na and K adducts</li> </ul>	<ul> <li>Mass accuracy of deconvoluted FLP mass ≤ 5 ppm</li> <li>% Fractional abundance of Na, and K adducts ≤ 10%</li> </ul>

		Decor	nvoluted M	ass Identific	ation			
Sequence Details	5							
Name:		Oligo_SST_OE240	_July7_2022			06/Jul/22 1	:38:06	
Directory:		Oligos				Administrator		
Data Vault		ChromeleonLocal				19/Jul/22 1	.09:39	
No. of Injections:		12				Administrator		
Deconvoluted m	ass overview				Component 1			
Inj. No.	Oligonucleotide	Position	TargetAccurac	y ExpectedMass	Component Identification	Measured Mass	Delta Mass	Pass or Fail
			ppm	Da		Da	ppm	
6	ST_MX3_05_MSC	Y:D1	10.0	3082.5493	Full length product	3082.5444	1.6	Pass
7	ST_MX3_06_MSC	Y:D1	10.0	6227.0543	Full length product	6227.0451	1.5	Pass
8	ST_MX3_07_MSC	Y:D1	10.0	9371.5593	Full length product	9371.5442	1.6	Pass
9	ST_MX3_08_MS0	Y:D1	10.0	12516.0643	Full length product	12516.0475	1.3	Pass
10	ST_MX3_08_MSC	Y:D1	10.0	15660.5693	Full length product	15660.5436	1.6	Pass
11	ST MX3 08 MSC	Y:D1	10.0	17249.8309	Full length product	17249.7875	2.5	Pass

#### **Oligonucleotide SET**

- Oligonucleotide standards (6 unmodified, ssDNA sequences)
- A sequence containing 10 injections using full MS method only, can be seamlessly deployed using Chromeleon eWorkflow procedure
- Evaluates LC and MS instrument performance related metrics that are important for oligonucleotide applications based on pre-defined acceptance criteria with pass or fail status

# **Oligonucleotide SET**

### System performance tested against pre-defined acceptance criteria

Performance check	Oligonucleotides Sequence	System performance metrics	Acceptance criteria
LC-MS test	<ol> <li>GAG CGG CTG T (10mer)</li> <li>GAG CGG CTG TGA GCG GCT GT (20mer)</li> <li>GAG CGG CTG TGA GCG GCT GTG AGC GGC TGT (30mer)</li> <li>GAG CGG CTG TGA GCG GCT GTG AGC GGC TGT GAG CGG CTG T (40mer)</li> <li>GAG CGG CTG TGA GCG GCT GTG AGC GGC TGT GAG CGG CTG TGA GCG GCT GT</li> </ol>	<ul> <li>Retention time reproducibility</li> <li>Peak area reproducibility</li> <li>Peak height reproducibility</li> <li>Peak height range</li> <li>Peak width at 10% height reproducibility</li> <li>Peak width at 10% height</li> </ul>	<ul> <li>RT %RSD ≤ 2%</li> <li>Peak area %RSD ≤ 10%</li> <li>Peak height %RSD ≤ 10%</li> <li>Peak height range between 2E7 to 2E8 counts</li> <li>Peak width at 10% height %RSD ≤ 10%</li> <li>Peak width at 10% height ≤ 0.5 min</li> </ul>
Intact mass deconvolution	(50mer) 6. GAG CGG CTG TGA GCG GCT GTG AGC GGC TGT GAG CGG CTG TGA GCG GCT GTG AGC G (55mer)	<ul> <li>Mass accuracy of deconvoluted FLP mass</li> <li>% Fractional abundance of Na and K adducts</li> </ul>	<ul> <li>Mass accuracy of deconvoluted FLP mass ≤ 5 ppm</li> <li>% Fractional abundance of Na, and K adducts ≤ 10%</li> </ul>

#### **Oligonucleotide SET**

- Oligonucleotide standards (6 unmodified, ssDNA sequences)
- A sequence containing 10 injections using full MS method only, can be seamlessly deployed using Chromeleon eWorkflow procedure
- Evaluates LC and MS instrument performance related metrics that are important for oligonucleotide applications based on pre-defined acceptance criteria with pass or fail status



## **Summary of Benefits**

- BioPharma Finder 5.0 software provides confident impurity identification base-by-base with localization of modifications
- Orbitrap Exploris 240 mass spectrometer and Orbitrap Exploris MX detector can achieve comparable quantitative performance for oligo impurities profiling
- Chromeleon eWorkflow procedure facilitates direct method transfer between Orbitrap Exploris 240 mass spectrometer and Orbitrap Exploris MX mass detectors for consistent quantitation of oligonucleotide impurities
- Oligo SET evaluates system performance against a comprehensive set of acceptance criteria that are designed for oligonucleotide applications

- Orbitrap Exploris 240 mass spectrometer provides up to 240,000 mass resolution for isotopic resolution of 100mer
- Vanquish Horizon UHPLC system coupled with a DNAPac RP column provides robust and reproducible separation of oligonucleotides and impurities
- ChromeCare solvents minimize metal adduction formation, and results in accurate mass determination

# Thank you

28 Proprietary & Confidential | hao.yang@thermofisher.com | 7/17/2022